Vergoeding 2016-2020 voor ATC-subgroep J05AB : Nucleosiden en nucleotiden (excl. reverse-transcr-remmers)
- Raming voor de totale Zvw-populatie
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| J05AB01 Aciclovir (Zovirax ®) | 386.510 | 370.840 | 321.080 | 264.360 | 429.920 |
| J05AB04 Nucleosiden en nucleotiden (excl. reverse-transcr-remmers) | 55.110 | 5.384 | . | . | . |
| J05AB06 Ganciclovir (Cymevene ®) | 2.348 | 44 | . | 165 | 165 |
| J05AB09 Famciclovir | 1.469.800 | 1.462.200 | 1.321.500 | 1.263.500 | 1.600.700 |
| J05AB11 Valaciclovir (Zelitrex ®) | 1.327.100 | 1.185.600 | 1.640.600 | 1.971.000 | 3.059.000 |
| J05AB14 Valganciclovir (Valcyte ®) | 4.896.100 | 2.792.100 | 1.107.300 | 1.063.000 | 714.350 |
| Totaal | 8.136.968 | 5.816.168 | 4.390.480 | 4.562.025 | 5.804.135 |